BR0213398A - Sal de alendronato, alendronato monossódico, processos para a produção dos mesmos, composição farmacêutica, e, método para inibição da ressorção óssea em um paciente - Google Patents

Sal de alendronato, alendronato monossódico, processos para a produção dos mesmos, composição farmacêutica, e, método para inibição da ressorção óssea em um paciente

Info

Publication number
BR0213398A
BR0213398A BR0213398-9A BR0213398A BR0213398A BR 0213398 A BR0213398 A BR 0213398A BR 0213398 A BR0213398 A BR 0213398A BR 0213398 A BR0213398 A BR 0213398A
Authority
BR
Brazil
Prior art keywords
alendronate
patient
processes
production
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
BR0213398-9A
Other languages
English (en)
Inventor
Yusuf Khwaja Hamied
Dhanmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924125&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0213398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of BR0213398A publication Critical patent/BR0213398A/pt
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"SAL DE ALENDRONATO, ALENDRONATO MONOSSóDICO, PROCESSOS PARA A PRODUçãO DOS MESMOS, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA INIBIçãO DA RESSORçãO óSSEA EM UM PACIENTE". Um sal de alendronato farmaceuticamente aceitável em uma forma amorfa.
BR0213398-9A 2001-10-18 2002-10-18 Sal de alendronato, alendronato monossódico, processos para a produção dos mesmos, composição farmacêutica, e, método para inibição da ressorção óssea em um paciente Withdrawn BR0213398A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0125081A GB2383042A (en) 2001-10-18 2001-10-18 Amorphous alendronate sodium
PCT/GB2002/004730 WO2003033508A1 (en) 2001-10-18 2002-10-18 Pharmaceutically acceptable alendronate salts in amorphous form

Publications (1)

Publication Number Publication Date
BR0213398A true BR0213398A (pt) 2005-01-11

Family

ID=9924125

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213398-9A Withdrawn BR0213398A (pt) 2001-10-18 2002-10-18 Sal de alendronato, alendronato monossódico, processos para a produção dos mesmos, composição farmacêutica, e, método para inibição da ressorção óssea em um paciente

Country Status (22)

Country Link
US (1) US7112577B2 (pt)
EP (1) EP1436303B1 (pt)
JP (1) JP4490100B2 (pt)
KR (1) KR20040053186A (pt)
AT (1) ATE338761T1 (pt)
AU (1) AU2002334200B2 (pt)
BR (1) BR0213398A (pt)
CA (1) CA2463815C (pt)
CL (1) CL2004001372A1 (pt)
DE (1) DE60214576T2 (pt)
EC (1) ECSP045067A (pt)
ES (1) ES2271375T3 (pt)
GB (1) GB2383042A (pt)
HK (1) HK1066011A1 (pt)
IL (1) IL161360A0 (pt)
MX (1) MXPA04003549A (pt)
NZ (1) NZ532292A (pt)
PT (1) PT1436303E (pt)
RU (1) RU2334751C2 (pt)
TN (1) TNSN04067A1 (pt)
WO (1) WO2003033508A1 (pt)
ZA (1) ZA200403024B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057136A2 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
EP1723157B2 (en) † 2004-02-26 2017-02-08 Zentiva, k.s. Amorphous forms of risedronate monosodium
DE602005001873T2 (de) 2004-03-03 2008-04-24 Chemi S.P.A., Cinisello Balsamo Amorphe 3-Pyridyl-1-Hydroxyethyliden-1,1-Bisphosphonsäure Mononatriumsalz und Verfahren zu deren Herstellung
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
AU2013315619B2 (en) * 2012-09-11 2018-02-08 Astellas Pharma Inc. Formulations of enzalutamide
US20150239848A1 (en) * 2012-09-11 2015-08-27 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
MX2018013742A (es) * 2016-05-09 2019-08-01 Anacor Pharmaceuticals Inc Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
WO2017218957A1 (en) * 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Solid state forms of spiro-oxindole compounds
EP3510021A1 (en) * 2016-09-06 2019-07-17 Indena S.p.A. Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
KR102592899B1 (ko) * 2017-02-01 2023-10-24 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
MX2019011649A (es) * 2017-03-30 2019-12-19 Merck Patent Gmbh Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.
WO2019104134A1 (en) * 2017-11-22 2019-05-31 Agios Pharmaceuticals, Inc. Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
DK0833643T3 (da) * 1995-06-06 2005-05-30 Merck & Co Inc Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
PL346347A1 (en) 1998-08-27 2002-02-11 Teva Pharma Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
ATE238315T1 (de) 1998-12-10 2003-05-15 Aesgen Inc Verfahren zur herstellung von dinatriumpamidronat
AU7902800A (en) 1999-10-26 2001-05-08 A/S Gea Farmaceutisk Fabrik Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use

Also Published As

Publication number Publication date
AU2002334200B2 (en) 2008-04-03
MXPA04003549A (es) 2004-07-22
HK1066011A1 (en) 2005-03-11
PT1436303E (pt) 2006-12-29
ES2271375T3 (es) 2007-04-16
JP4490100B2 (ja) 2010-06-23
JP2005521636A (ja) 2005-07-21
DE60214576T2 (de) 2007-08-30
US20040259846A1 (en) 2004-12-23
KR20040053186A (ko) 2004-06-23
RU2334751C2 (ru) 2008-09-27
CA2463815A1 (en) 2003-04-24
EP1436303B1 (en) 2006-09-06
WO2003033508A1 (en) 2003-04-24
ATE338761T1 (de) 2006-09-15
TNSN04067A1 (en) 2006-06-01
EP1436303A1 (en) 2004-07-14
GB0125081D0 (en) 2001-12-12
ECSP045067A (es) 2004-07-23
DE60214576D1 (de) 2006-10-19
CL2004001372A1 (es) 2005-05-06
RU2004113306A (ru) 2005-10-10
US7112577B2 (en) 2006-09-26
GB2383042A (en) 2003-06-18
IL161360A0 (en) 2004-09-27
CA2463815C (en) 2009-04-07
ZA200403024B (en) 2005-03-30
NZ532292A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
BR0213398A (pt) Sal de alendronato, alendronato monossódico, processos para a produção dos mesmos, composição farmacêutica, e, método para inibição da ressorção óssea em um paciente
BR0308901A (pt) ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
DE60329729D1 (de) Implantierbare Vorrichtung zur Arzneimittelverabreichung
FI971974A (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
AU2002344752A1 (en) Method and apparatus for sterilizing or disinfecting a region through a bandage
BR0211102B1 (pt) método para a produção de uma prótese dentária.
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
WO2002011764A3 (en) PHARMACEUTICAL COMPOSITIONS
GEP20063951B (en) Controlled release polymeric compositions of bone growth promoting compounds
HUP0303013A2 (hu) Gyógyszer csontelhalás kezelésére és olyan betegek gondozására, akiknél a csontelhalás kialakulásának kockázata áll fenn
BR0100558A (pt) Composições e métodos para tratar a osteoporose
ATE367152T1 (de) Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung
UA83900C2 (en) Amorphous forms of risedronate monosodium
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
DE50115451D1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
UA26204C2 (uk) Спосіб запобігаhhя деградації кісткового протеза
AR027853A1 (es) Composicion para revestimiento hidrofilica, enlazada convalentemente, para implantes quirurgicos, el implante y el metodo para revestirlo.
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
EA200501221A1 (ru) Фармацевтическая композиция алендроновой кислоты, ее солей или сложных эфиров и способ ее получения
UY26990A1 (es) Nuevas composiciones de medicamentos
FR2827777B1 (fr) Procede et machine de sterilisation par plasma
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 4A., 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.